These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. Kopschina Feltes P; Doorduin J; Klein HC; Juárez-Orozco LE; Dierckx RA; Moriguchi-Jeckel CM; de Vries EF J Psychopharmacol; 2017 Sep; 31(9):1149-1165. PubMed ID: 28653857 [TBL] [Abstract][Full Text] [Related]
3. The molecular mechanism of polysaccharides in combating major depressive disorder: A comprehensive review. Kong H; Xu T; Wang S; Zhang Z; Li M; Qu S; Li Q; Gao P; Cong Z Int J Biol Macromol; 2024 Feb; 259(Pt 2):129067. PubMed ID: 38163510 [TBL] [Abstract][Full Text] [Related]
4. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. Barden N J Psychiatry Neurosci; 2004 May; 29(3):185-93. PubMed ID: 15173895 [TBL] [Abstract][Full Text] [Related]
5. The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences. Millard SJ; Weston-Green K; Newell KA Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109908. PubMed ID: 32145362 [TBL] [Abstract][Full Text] [Related]
6. The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs. Markov DD; Dolotov OV; Grivennikov IA Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047638 [TBL] [Abstract][Full Text] [Related]
7. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Ressler KJ; Nemeroff CB Depress Anxiety; 2000; 12 Suppl 1():2-19. PubMed ID: 11098410 [TBL] [Abstract][Full Text] [Related]
8. An initial exploration of hair cortisol responses to antidepressants in unmedicated patients with depression. Song X; Cui W; Peng Z; Zhao L; Yu X; Li T; Cui L; Ma X J Int Med Res; 2020 Mar; 48(3):300060519889431. PubMed ID: 31849246 [TBL] [Abstract][Full Text] [Related]
9. Astroglial Connexin 43-Mediated Gap Junctions and Hemichannels: Potential Antidepressant Mechanisms and the Link to Neuroinflammation. Lei L; Wang YT; Hu D; Gai C; Zhang Y Cell Mol Neurobiol; 2023 Nov; 43(8):4023-4040. PubMed ID: 37875763 [TBL] [Abstract][Full Text] [Related]
10. The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls. Sorgdrager FJH; Doornbos B; Penninx BWJH; de Jonge P; Kema IP J Affect Disord; 2017 Nov; 222():32-39. PubMed ID: 28668713 [TBL] [Abstract][Full Text] [Related]
11. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Mason BL; Pariante CM Drug News Perspect; 2006 Dec; 19(10):603-8. PubMed ID: 17299602 [TBL] [Abstract][Full Text] [Related]
12. Curcumin as a putative antidepressant. Seo HJ; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU Expert Rev Neurother; 2015 Mar; 15(3):269-80. PubMed ID: 25644944 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits. Maric NP; Adzic M Psychiatr Danub; 2013 Sep; 25(3):299-305. PubMed ID: 24048401 [TBL] [Abstract][Full Text] [Related]
14. Converged avenues: depression and Alzheimer's disease- shared pathophysiology and novel therapeutics. Bajaj S; Mahesh R Mol Biol Rep; 2024 Jan; 51(1):225. PubMed ID: 38281208 [TBL] [Abstract][Full Text] [Related]
15. Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function. Budziszewska B Pol J Pharmacol; 2002; 54(4):343-9. PubMed ID: 12523487 [TBL] [Abstract][Full Text] [Related]
16. Vasopressin as a target for antidepressant development: an assessment of the available evidence. Scott LV; Dinan TG J Affect Disord; 2002 Nov; 72(2):113-24. PubMed ID: 12200202 [TBL] [Abstract][Full Text] [Related]
17. Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Unschuld PG; Ising M; Roeske D; Erhardt A; Specht M; Kloiber S; Uhr M; Müller-Myhsok B; Holsboer F; Binder EB Neuropsychopharmacology; 2010 Jun; 35(7):1583-92. PubMed ID: 20237460 [TBL] [Abstract][Full Text] [Related]
18. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. Chang HS; Won E; Lee HY; Ham BJ; Lee MS Behav Brain Res; 2015 Oct; 292():116-24. PubMed ID: 26055202 [TBL] [Abstract][Full Text] [Related]
19. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function. Nikisch G Neuro Endocrinol Lett; 2009 Mar; 30(1):11-6. PubMed ID: 19300389 [TBL] [Abstract][Full Text] [Related]
20. The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a randomized trial. Sarubin N; Nothdurfter C; Schüle C; Lieb M; Uhr M; Born C; Zimmermannc R; Bühner M; Konopka K; Rupprecht R; Baghai TC J Psychiatr Res; 2014 Jun; 53():76-83. PubMed ID: 24655586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]